3Adelsberger H, Quasthof G,Grosskreutz J,et al. The chemotherapeutic oxaliplatin alters vohagegated Na (+) channel kinetics on rat sensory neurons[J]. Eur J Pharma- c01,2000,406( 1 ) : 2532.
4Mikhai! SE,Sun JF, Marshall JL. Safety of capecitabine : A review[J]. Expert Opin Drug Saf, 2010,9(5) : 831-841.
5Nobuyasu Yoshimoto,Toshinari Yamashita, et al. Impact of prophylactic pyridoxine on occurrence of hand-foot syn- drome in patients receiving capecitabine for advanced or metastatic breast cancer[J]. Breast Cancer, 2010, 17 (4) : 298-302.
6Cheng Y, Song W. Efficacy of FOLFOXIRI versus XELOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer[J]. Int J Clin Exp Med,2015, 8(10) : 18713-18720.
7Back KK,Lee J, Park SH, et al. Oxaliplatin-induced chronic peripheral neurotoxicity :A prospective analysis in patients with colorectal cancer[J]. Cancer Res Treat,2010, 42(4) : 185-190.
8Hoff PM, Saad ED, Costa F, et al. Literature review and practical aspects on the management of oxaliplatin-associ- ated toxicity[J]. Clin Colorectal Cancer, 2012,11 (2) : 93- 100.
9Von Moos R,Thuerlimann BJK, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts[J]. Eur J Cancer, 2008,44(6) :781-790.
10Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral ery- thema secondary to high-dose chemotherapy for acute myelogenous leukemia[J]. Ann Intern Med, 1982,97 : 61- 62.
